How is someone assessed for liver transplant surgery?

Autore: Professor Roger Williams CBE
Pubblicato: | Aggiornato: 26/10/2023
Editor: Laura Burgess

Current survival figures in adults for a liver transplant are near 100% at one year with around 70% five and ten-year survivals. There are several long-term surviving liver transplant patients in the UK who are aged between 30 to 40 years, and who are in good health.

With the number of donor organs increasing as it has over the past year, it is likely that more transplants will be carried out in the UK and that the duration on the waiting list after acceptance will reduce. It is also possible that the criteria for suitability will be extended as may the types of disease which can be treated by a transplant.


Professor Roger Williams, CBE, Director of the Institute of Hepatology, London and Honorary Professor of Hepatology, King’s College London explains how a patient is assessed in order to have liver transplant surgery.
 

What is the process of assessment for a liver transplant with you?

Two main questions will be asked initially, namely, have all other forms of therapy been tried for the patient being considered and whether the chances of surviving 12 months without a transplant are less than 50%. In other words, the patient’s prognosis is poor and there is no other possibility remaining for that patient apart from a liver transplant.
 

What are you looking for during the assessment?

In the clinical assessment of the patient for the transplant procedure, attention will be directed to the presence of significant co-morbidity. In this connection, major heart disease that is not amenable to corrective measures (e.g. stenting) or chronic obstructive airways disease with severe limitation of respiratory capacity, will rule out the possibility of a liver transplant, as will severe kidney disease, which is known to greatly reduce the chances of a successful procedure.

If the kidney impairment is directly or indirectly related to the liver disease and with a chance of it being improved by the transplant, with the subsequent normal liver function, then this would be taken into consideration.

Increasingly the patient’s general condition and muscle strength are considered in the assessment with the determination of a so-called Frailty Index. In instances where this is low and where it is considered improvement could be obtained by intensive feeding over a period of a few months or by an exercise programme, then further assessment will be deferred until that has happened.

A psychiatric assessment will be particularly important in patients with alcohol-related liver disease or liver disease related to addictive drugs to ensure that the risk of relapse following the liver transplant are low.

Whereas in the past, active hepatitis C infection was considered a contra-indication, now with the availability of the new directly acting agents this is no longer so. These drugs can be given following the transplant to cure any infection that has been transmitted. The efficacy of the new drugs in clearing the virus has allowed the use of hepatitis C positive donor organs.
 

Primary hepatocellular and other liver tumours

The experience here is that only with a relatively small volume of tumour (one major lesion of 5cm diameter or 3 less than 3cm diameter) are the chances of tumour recurrence following a transplant reasonably low. Detailed CT and MRI imaging will be carried out not only to assess the size of intrahepatic tumours but also to exclude metastases of the tumour elsewhere.
 

Are there any other tests carried out?

Finally, technical aspects relating to the transplant that will be assessed on the basis of the clinical findings and results of the investigations including radiological and functional imaging. In particular, the presence a portal vein thrombosis, which is common in patients with cirrhosis, is a relatively strong contra-indication but will only rule it out if the thrombosis extends backwards into the superior mesenteric vein and when the thrombosis is related to tumour infiltration.
 

What happens if I am suitable?

The final selection for liver transplantation occurs at the implant centre that the patient is referred to. This may require several attendances as an outpatient and meetings with the transplant team as well as the transplant coordinator. The findings for that particular patient are finally discussed at a multi-disciplinary meeting before the patient is placed on the waiting list for it.
 

What happens if I am not suitable for liver transplant surgery?

If at any stage during the assessment the patient is considered unsuited for a transplant they will be referred back the original physicians and hospital along with full details of the tests on the same day. The specialists will make suggestions as to other possible treatments that could be tried.


Do not hesitate to make an appointment to see Professor Williams CBE if you would like to discuss your liver transplant options. 

*Tradotto con Google Translator. Preghiamo ci scusi per ogni imperfezione
Professor Roger Williams CBE

Professor Roger Williams CBE
Epatologia

Il professor Williams è il direttore dell'Istituto di epatologia , Londra e direttore medico della Fondazione per la ricerca sul fegato , un'organizzazione benefica registrata nel Regno Unito. Ricopre una posizione di epatologo consulente onorario al King's College Hospital .

L'Institute of Hepatology è un istituto di ricerca indipendente finanziato e gestito dalla Foundation for Liver Research, un ente di beneficenza istituito dal Professor Williams nel 1974. Ha lo status di affiliato al King's College London e al King's College Hospital. Tra il 1996 e il 2010 la Professoressa Williams fondò un importante istituto di ricerca presso l'University College di Londra e costruì un importante servizio clinico di epatologia presso l'University College Hospital. Durante quel periodo fu anche responsabile della creazione del centro epatico presso la London Clinic. Nella sua attuale posizione rimane vicino al rinomato Institute of Liver Studies del King's College Hospital, che ha iniziato da zero come unità epatica nel 1966. Per 30 anni è stato Director, costruendolo per diventare uno dei più grandi studi clinici e di ricerca unità epatiche in tutto il mondo. È stato responsabile, insieme al professor Sir Roy Calne, del primo pionieristico inizio dei trapianti di fegato nel Regno Unito.

È membro dell'Accademia delle scienze mediche, di Londra e del Royal College of Physicians, dove è stato Vicepresidente clinico e direttore dell'Ufficio internazionale. È destinatario di numerose borse, medaglie e premi onorari tra cui l'American Society of Transplantation Senior Achievement Award nel 2004, Hans Popper Lifetime Achievement nel 2008, il Distinguished Service Award dell'International Liver Transplant Society nel 2011 e nel 2013 il Distinguished Premio alla carriera dell'American Association for Study of Liver Disease. Dal 2013 è stato presidente della Commissione Lancet in Malattia del fegato nel Regno Unito che, con il suo corpo di esperti, i suoi rapporti annuali e le riunioni parlamentari, ha affrontato le principali cause dello stile di vita delle malattie del fegato nel paese, vale a dire l'alcol, l'epatite virale e obesità.

I suoi principali interessi clinici e di ricerca sono l'insufficienza epatica acuta e cronica , i dispositivi di supporto epatico , il trapianto di fegato , le complicanze o la cirrosi e la gestione dell'epatite virale .

Il professor Williams ha una vasta esperienza nel fornire relazioni mediche specialistiche e può essere contattato tramite il suo ufficio presso l'Istituto di epatologia.

*Tradotto con Google Translator. Preghiamo ci scusi per ogni imperfezione


  • Altri trattamenti d'interesse
  • Gastroscopia
    Endoscopia
    Colonoscopia
    Fegato grasso
    Calcoli vescicolari o biliari
    Chirurgia del fegato
    Itterizia
    Dolori addominali nel bambino
    Cirrosi
    Biopsia epatica
    Questo sito web utilizza cookie propri e di terze parti per raccogliere informazioni al fine di migliorare i nostri servizi, per mostrarle la pubblicità relativa alle sue preferenze, nonché analizzare le sue abitudini di navigazione. L'utente ha la possibilità di configurare le proprie preferenze QUI.